Aytu Biopharma (AYTU) Cash from Investing Activities (2015 - 2025)
Aytu Biopharma (AYTU) posted quarterly Cash from Investing Activities of -$17000.0 for Q4 2025, down 111.72% year-over-year from $145000.0 in Q4 2024, and up 99.44% quarter-over-quarter from -$3.0 million in Q2 2025.
Aytu Biopharma (AYTU) Cash from Investing Activities (2015 - 2025) Analysis & Trends
Aytu Biopharma (AYTU) has reported Cash from Investing Activities for 11 consecutive years, with -$17000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Investing Activities fell 111.72% year-over-year to -$17000.0; the TTM figure through Mar 2026 stood at -$3.0 million (down 817.26% YoY), while the FY2025 annual figure was -$2.6 million, down 678.12% from the prior year.
- Cash from Investing Activities rose to -$17000.0 in Q4 2025 per AYTU's latest filing, from -$3.0 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $381000.0 in Q3 2024 and bottomed at -$3.1 million in Q4 2021.
- Historically, Cash from Investing Activities has averaged -$483166.7 across 5 years, with a median of -$57000.0 in 2024.
- Annual changes were most pronounced in 2021 — Cash from Investing Activities tumbled 10070.0% — and 2024, when it surged 601.32%.
- Aytu Biopharma's Cash from Investing Activities stood at -$3.1 million in 2021, then surged by 99.84% to -$5000.0 in 2022, then tumbled by 3380.0% to -$174000.0 in 2023, then jumped by 183.33% to $145000.0 in 2024, then tumbled by 111.72% to -$17000.0 in 2025.
- Business Quant data shows AYTU's Cash from Investing Activities at -$17000.0 in Q4 2025, -$3.0 million in Q2 2025, and -$69000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Aytu Biopharma | 24.70 Mn | -2.01 Mn | 7.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -17,000.00 |
| Dec 31, 2025 | -17,000.00 |
| Jun 30, 2025 | -3.02 Mn |
| Jun 30, 2025 | -3.02 Mn |
| Mar 31, 2025 | -69,000.00 |
| Mar 31, 2025 | -69,000.00 |
| Dec 31, 2024 | 145,000.00 |
| Dec 31, 2024 | 145,000.00 |
| Sep 30, 2024 | 381,000.00 |
| Sep 30, 2024 | 381,000.00 |
| Jun 30, 2024 | -34,000.00 |
| Jun 30, 2024 | -34,000.00 |
| Mar 31, 2024 | -45,000.00 |
| Mar 31, 2024 | -45,000.00 |
| Dec 31, 2023 | -174,000.00 |
| Dec 31, 2023 | -174,000.00 |
| Sep 30, 2023 | -76,000.00 |
| Sep 30, 2023 | -76,000.00 |
| Jun 30, 2023 | -155,000.00 |
| Jun 30, 2023 | -155,000.00 |